Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

about

Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.

P2860

Q35820496-4FE95120-E2F0-46D9-B5E2-3AAD4EE71988

P2860

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

Item

http://www.wikidata.org/entity/Q37309845

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Breast cancer follow-up strate ...... al trials: a systematic review

@en

Breast cancer follow-up strate ...... l trials: a systematic review.

@nl

type

Item

label

Breast cancer follow-up strate ...... al trials: a systematic review

@en

Breast cancer follow-up strate ...... l trials: a systematic review.

@nl

prefLabel

Breast cancer follow-up strate ...... al trials: a systematic review

@en

Breast cancer follow-up strate ...... l trials: a systematic review.

@nl

P1476

Breast cancer follow-up strate ...... al trials: a systematic review

@en

P2093

Antonino Grassadonia

http://www.w3.org/2001/XMLSchema#string

Giada Cortese

http://www.w3.org/2001/XMLSchema#string

Stefano Iacobelli

http://www.w3.org/2001/XMLSchema#string

Teresa Gamucci

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Cancer statistics, 2013

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012.

Follow-up strategies for women treated for early breast cancer.

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

P2888

1756-9966-32-89

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-9966-32-89

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P5008

ScienceSource

P577

2013-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259804858

http://www.w3.org/2001/XMLSchema#string

P6179

1014370005

http://www.w3.org/2001/XMLSchema#string

P698

24438135

http://www.w3.org/2001/XMLSchema#string

P921

breast cancer

phase III clinical trial

breast neoplasm

biomedical investigative technique

P932

3828573

http://www.w3.org/2001/XMLSchema#string

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

about

P2860

P2860

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P478

P50

P5008

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P478

P50

P5008

P577

P5875

P6179

P698

P921

P932